Loading institutional data...
Loading institutional data...
Held by 292 of 5,944 reporting institutions (94th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $42.74 today, the market must believe free cash flow compounds -6.6%/yr for a decade (off $262M normalized FCF).
The market's -6.6% is more conservative than its 4-yr track record.
2-stage DCF · 0.06B shares · net debt -$589M
mean 39.4% · volatility σ 27% · implied rate exceeded in 4/4 yrs
Central path = implied -6.6%/yr growth; shaded band = ±1σ (27%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $868.5M 100.0% | $714.7M 100.0% | $582.0M 100.0% | $437.9M 100.0% | $305.4M 100.0% | $159.7M 100.0% | $6.0M 100.0% |
| Cost of Revenue | $198.3M 22.8% | $156.8M 21.9% | $121.2M 20.8% | $83.5M 19.1% | $55.5M 18.2% | $27.7M 17.4% | $1.6M 26.3% |
| Gross Profit | $670.1M 77.2% | $557.9M 78.1% | $460.8M 79.2% | $354.4M 80.9% | $249.9M 81.8% | $132.0M 82.6% | $4.4M 73.7% |
| Research & Development | $189.6M 21.8% | $145.8M 20.4% | $76.1M 13.1% | $70.9M 16.2% | $30.4M 9.9% | $19.4M 12.2% | $69.6M 1160.9% |
| Selling, General & Admin | $152.5M 17.6% | $110.4M 15.4% | $95.3M 16.4% | $84.0M 19.2% | $63.9M 20.9% | $39.7M 24.9% | $36.4M 607.3% |
| Total Operating Expenses | $461.6M 53.2% | $367.1M 51.4% | $268.8M 46.2% | $234.2M 53.5% | $162.4M 53.2% | $115.0M 72.0% | $150.3M 2507.5% |
| Operating Income | $208.5M 24.0% | $190.8M 26.7% | $192.0M 33.0% | $120.2M 27.4% | $87.5M 28.7% | $17.0M 10.6% | -$145.9M -2433.8% |
| Interest Expense | $14.6M 1.7% | $17.5M 2.4% | $23.8M 4.1% | $18.8M 4.3% | $24.2M 7.9% | $28.6M 17.9% | $7.4M 122.8% |
| Other Income (Expense), net | -$680K -0.1% | -$68K -0.0% | $159K 0.0% | $169K 0.0% | $16K 0.0% | -$3.1M -1.9% | — |
| Pretax Income | $215.1M 24.8% | $191.8M 26.8% | $173.4M 29.8% | $104.7M 23.9% | $37.4M 12.3% | -$36.9M -23.1% | -$152.0M -2535.1% |
| Income Tax Expense | $56.4M 6.5% | $46.3M 6.5% | $44.5M 7.7% | -$76.8M -17.5% | $2.8M 0.9% | — | — |
| Net Income | $158.7M 18.3% | $145.5M 20.4% | $128.9M 22.1% | $181.5M 41.4% | $34.6M 11.3% | -$36.9M -23.1% | -$152.0M -2535.1% |
| Per Share | |||||||
| EPS (Basic) | $2.76 | $2.56 | $2.17 | $3.07 | $0.60 | $-2.48 | $-24.07 |
| EPS (Diluted) | $2.71 | $2.51 | $2.13 | $2.97 | $0.58 | $-2.48 | $-24.07 |
| Weighted Avg Shares (Basic) | 57.5M | 56.9M | 59.5M | 59.2M | 57.5M | 25.8M | 7.8M |
| Weighted Avg Shares (Diluted) | 58.5M | 57.9M | 60.4M | 61.1M | 59.2M | 25.8M | 7.8M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $348M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 7 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 15%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 7 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $753M covers all $185M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2024-09-30 (10-Q).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~9.0% on $164M of debt.
Cash of $753M fully covers short-term debt of $20M.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 6-yr range · 37th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 6-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cost of Revenue | 26.3 | 17.4 | 18.2 | 19.1 | 20.8 | 21.9 | 22.8 |
| Gross Profit | 73.7 | 82.6 | 81.8 | 80.9 | 79.2 | 78.1 | 77.2 |
| R&D | 1160.9 | 12.2 | 9.9 | 16.2 | 13.1 | 20.4 | 21.8 |
| SG&A | 607.3 | 24.9 | 20.9 | 19.2 | 16.4 | 15.4 | 17.6 |
| Operating Income | -2433.8 | 10.6 | 28.7 | 27.4 | 33.0 | 26.7 | 24.0 |
| Income Tax | — | — | 0.9 | -17.5 | 7.7 | 6.5 | 6.5 |
| Net Income | -2535.1 | -23.1 | 11.3 | 41.4 | 22.1 | 20.4 | 18.3 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on HRMY: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| HRMY | $2.5B | 15.8× | — | 2.8× | 21.5% | 77.2% | 18.3% | 18.2% | 15.3% | — | 292 |
Peers = companies sharing HRMY's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position